Adiabatic Approximation in the Density Matrix Approach: Non-Degenerate Systems

We study the adiabatic limit in the density matrix approach for a quantum system coupled to a weakly dissipative medium. The energy spectrum of the quantum model is supposed to be non-degenerate. In the absence of dissipation, the geometric phases for periodic Hamiltonians obtained previously by M.V. Berry are recovered in the present approach. We determine the necessary condition satisfied by the coefficients of the linear expansion of the non-unitary part of the Liouvillian in order to the imaginary phases acquired by the elements of the density matrix, due to dissipative effects, be geometric. The results derived are model-independent. We apply them to spin 1/2 model coupled to reservoir at thermodynamic equilibrium.Comment: 24 pages (new version), accepted for publication in Physica

The η\eta-3N problem with separable interactions

The $\eta$-3N-interaction is studied within the four-body Faddeev-Yakubovsky theory adopting purely separable forms for the two- and three-body subamplitudes, limiting the basic two-body interactions to s-waves only. The corresponding separable approximation for the integral kernels is obtained by using the Hilbert-Schmidt procedure. Results are presented for the $\eta$-$^3$H scattering amplitude and for the total elastic cross section for energies below the triton break-up threshold.Comment: revised version accepted for Phys. Rev. C, 16 pages revtex including 6 eps-figures, formal part shortene

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Background: Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in HER2-positive disease treated with dual HER2-blockade without chemotherapy. Methods: A research-based PAM50 assay was applied in 422 HER2-positive tumors from five II-III clinical trials (SOLTI-PAMELA, TBCRC023, TBCRC006, PER-ELISA, EGF104090). In SOLTI-PAMELA, TBCRC023, TBCRC006, and PER-ELISA, all patients had early disease and were treated with neoadjuvant lapatinib or pertuzumab plus trastuzumab for 12-24 weeks. Primary outcome was pathological complete response (pCR). In EGF104900, 296 women with advanced disease were randomized to receive either lapatinib alone or lapatinib plus trastuzumab. Progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) were evaluated. Results: A total of 305 patients with early and 117 patients with advanced HER2-positive disease were analyzed. In early disease, HER2-E represented 83.8% and 44.7% of ERBB2-high and ERBB2-low tumors, respectively. Following lapatinib and trastuzumab, the HER2-E and ERBB2 (HER2-E/ERBB2)-high group showed a higher pCR rate compared to the rest (44.5%, 95% confidence interval [CI] = 35.4% to 53.9% vs 11.6%, 95% CI = 6.9% to 18.0%; adjusted odds ratio [OR] = 6.05, 95% CI = 3.10 to 11.80, P <. 001). Similar findings were observed with neoadjuvant trastuzumab and pertuzumab (pCR rate of 66.7% in HER2-E/ERBB2-high, 95% CI = 22.3% to 95.7% vs 14.7% in others, 95% CI = 4.9% to 31.1%; adjusted OR = 11.60, 95% CI = 1.66 to 81.10, P =. 01). In the advanced setting, the HER2-E/ERBB2-high group was independently associated with longer PFS (hazard ratio [HR] = 0.52, 95% CI = 0.35 to 0.79, P <. 001); higher ORR (16.3%, 95% CI = 8.9% to 26.2% vs 3.7%, 95% CI = 0.8% to 10.3%, P =. 02); and longer OS (HR = 0.66, 95% CI = 0.44 to 0.97, P =. 01). Conclusions: Combining HER2-E subtype and ERBB2 mRNA into a single assay identifies tumors with high responsiveness to HER2-targeted therapy. This biomarker could help de-escalate chemotherapy in approximately 40% of patients with HER2-positive breast cancer

Nuclear Electric Dipole Moment of 3He

A permanent electric dipole moment (EDM) of a physical system requires time-reversal (T) and parity (P) violation. Experimental programs are currently pushing the limits on EDMs in atoms, nuclei, and the neutron to regimes of fundamental theoretical interest. Here we calculate the magnitude of the PT-violating EDM of 3He and the expected sensitivity of such a measurement to the underlying PT-violating interactions. Assuming that the coupling constants are of comparable magnitude for pi-, rho-, and omega-exchanges, we find that the pion-exchange contribution dominates. Our results suggest that a measurement of the 3He EDM is complementary to the planned neutron and deuteron experiments, and could provide a powerful constraint for the theoretical models of the pion-nucleon PT-violating interaction.Comment: 6 pages, 1 figur

The Physiology of Vasodilatation

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/68237/2/10.1177_000331976101200602.pd